

# Suresh Sundram

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7024661/publications.pdf>

Version: 2024-02-01

89

papers

2,849

citations

257450

24

h-index

182427

51

g-index

96

all docs

96

docs citations

96

times ranked

4786

citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disorders. <i>Psychological Medicine</i> , 2022, 52, 3097-3115.	4.5	7
2	Moral injury related to immigration detention on Nauru: a qualitative study. <i>European Journal of Psychotraumatology</i> , 2022, 13, 2029042.	2.5	2
3	You canâ€™t have one without the other: The case for integrated perinatal and infant mental health services. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, , 000486742210838.	2.3	0
4	English language proficiency and hospital admissions via the emergency department by aged care residents in Australia: A mixedâ€‘methods investigation. <i>Health and Social Care in the Community</i> , 2022, 30, .	1.6	1
5	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. <i>Lancet Psychiatry</i> , the, 2022, 9, 477-486.	7.4	13
6	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	2.8	16
7	Maternal immune activation targeted to a window of parvalbumin interneuron development improves spatial working memory: Implications for autism. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 339-349.	4.1	21
8	Brain changes in NF-Î²B1 and epidermal growth factor system markers at peri-pubescence in the spiny mouse following maternal immune activation. <i>Psychiatry Research</i> , 2021, 295, 113564.	3.3	5
9	Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 595-607.	3.2	40
10	Understanding the Neurodevelopment of Children Born During the COVID-19 Pandemic. <i>Biological Psychiatry</i> , 2021, 89, S117.	1.3	0
11	Betacellulin - A Novel Therapeutic Target for Schizophrenia. <i>Biological Psychiatry</i> , 2021, 89, S381.	1.3	0
12	Dynamic face processing impairments are associated with cognitive and positive psychotic symptoms across psychiatric disorders. <i>NPJ Schizophrenia</i> , 2021, 7, 36.	3.6	6
13	Stronger Top-Down and Weaker Bottom-Up Frontotemporal Connections During Sensory Learning Are Associated With Severity of Psychotic Phenomena. <i>Schizophrenia Bulletin</i> , 2021, 47, 1039-1047.	4.3	7
14	The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2020, 46, 140-153.	4.3	31
15	Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders. <i>Psychological Medicine</i> , 2020, 50, 1475-1489.	4.5	12
16	Bazedoxifene â€“ a promising brain active SERM that crosses the blood brain barrier and enhances spatial memory. <i>Psychoneuroendocrinology</i> , 2020, 121, 104830.	2.7	8
17	Touchscreen Cognitive Performance following Maternal Immune Activation Targeting Early and Late Prenatal Neurodevelopmental Windows. <i>Biological Psychiatry</i> , 2020, 87, S235-S236.	1.3	1
18	Differential Expression Patterns of the TNF Pathway in Dorsolateral Prefrontal Cortical Regions (BA9/BA46) in Schizophrenia and Mood Disorder. <i>Biological Psychiatry</i> , 2020, 87, S271-S272.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Aberrant connectivity in auditory precision encoding in schizophrenia spectrum disorder and across the continuum of psychotic-like experiences. <i>Schizophrenia Research</i> , 2020, 222, 185-194.	2.0	3
20	Changes in Non-Coding RNA in Depression and Bipolar Disorder: Can They Be Used as Diagnostic or Theranostic Biomarkers?. <i>Non-coding RNA</i> , 2020, 6, 33.	2.6	6
21	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	1.0	24
22	Raloxifene recovers effects of prenatal immune activation on cognitive task-induced gamma power. <i>Psychoneuroendocrinology</i> , 2019, 110, 104448.	2.7	14
23	Evaluation of an alternative model for the management of clinical risk in an adult acute psychiatric inpatient unit. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 1102-1112.	3.8	5
24	The maternal immune activation model uncovers a role for the Arx gene in GABAergic dysfunction in schizophrenia. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 161-171.	4.1	26
25	4.1 COGNITIVE RESERVE ATTENUATES AGE-RELATED COGNITIVE DECLINE IN THE CONTEXT OF ACCELERATED BRAIN AGEING IN SCHIZOPHRENIA-SPECTRUM DISORDERS: EVIDENCE FOR ACTIVE COMPENSATION. <i>Schizophrenia Bulletin</i> , 2019, 45, S91-S92.	4.3	1
26	O8.8. THE NEURAL DYNAMICS OF BELIEF FORMATION: IMPAIRMENTS SPECIFIC TO THE SCHIZOPHRENIA SPECTRUM AND FEATURES THAT ALIGN ON THE PSYCHOSIS CONTINUUM. <i>Schizophrenia Bulletin</i> , 2019, 45, S186-S186.	4.3	0
27	Schizophrenia in the light of precision medicine: a time for reconsideration. <i>Sri Lanka Journal of Psychiatry</i> , 2019, 10, 1.	0.1	0
28	F15. DIFFERENTIAL EXPRESSION PATTERNS OF EPIDERMAL GROWTH FACTOR (EGF) AND IMMUNE SYSTEM MARKERS IN DORSOLATERAL PREFRONTAL (BA46) AND ORBITOFRONTAL (BA11) CORTICES IN SCHIZOPHRENIA AND MOOD DISORDER. <i>Schizophrenia Bulletin</i> , 2018, 44, S224-S224.	4.3	0
29	Development and validation of a mental health screening tool for asylum-seekers and refugees: the STAR-MH. <i>BMC Psychiatry</i> , 2018, 18, 69.	2.6	56
30	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. <i>Molecular Psychiatry</i> , 2018, 23, 1261-1269.	7.9	522
31	Neuregulin-1 (<i>NRG1</i>) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. <i>Psychological Medicine</i> , 2018, 48, 801-809.	4.5	10
32	Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities. <i>Schizophrenia Bulletin</i> , 2018, 44, 560-574.	4.3	44
33	Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders. <i>Psychiatry Research - Neuroimaging</i> , 2018, 281, 61-68.	1.8	10
34	Meta-analysis reveals associations between genetic variation in the 5â€² and 3â€² regions of Neuregulin-1 and schizophrenia. <i>Translational Psychiatry</i> , 2017, 7, e1004-e1004.	4.8	32
35	Sensory integration deficits support a dimensional view of psychosis and are not limited to schizophrenia. <i>Translational Psychiatry</i> , 2017, 7, e1118-e1118.	4.8	33
36	Accelerated Gray and White Matter Deterioration With Age in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 286-295.	7.2	168

#	ARTICLE	IF	CITATIONS
37	165. Differing Expression Pattern of Epidermal Growth Factor (EGF) and Immune System Markers between Schizophrenia and Mood Disorder in the Dorsolateral Prefrontal Cortex. <i>Biological Psychiatry</i> , 2017, 81, S68-S69.	1.3	1
38	Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. <i>Translational Psychiatry</i> , 2017, 7, 1280.	4.8	25
39	The mental health of refugees and asylum seekers on Manus Island. <i>Lancet, The</i> , 2017, 390, 2534-2536.	13.7	7
40	Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 225.	2.6	20
41	M124. Perception of Socio-Emotional Information in Dynamic Gait in Inpatients With Schizophrenia Spectrum Disorders. <i>Schizophrenia Bulletin</i> , 2017, 43, S255-S256.	4.3	0
42	Neuregulin-1 and schizophrenia in the genome-wide association study era. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 387-409.	6.1	68
43	Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence. <i>Psychiatry Research</i> , 2016, 240, 260-264.	3.3	8
44	Selective impairment of global motion integration, but not global form detection, in schizophrenia and bipolar affective disorder. <i>Schizophrenia Research: Cognition</i> , 2016, 3, 11-14.	1.3	7
45	The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes. <i>NPJ Schizophrenia</i> , 2015, 1, 15043.	3.6	60
46	Mental Disorders in Asylum Seekers. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 28-32.	1.0	83
47	Demoralisation syndrome does not explain the psychological profile of community-based asylum-seekers. <i>Comprehensive Psychiatry</i> , 2015, 63, 55-64.	3.1	12
48	Social factors ameliorate psychiatric disorders in community-based asylum seekers independent of visa status. <i>Psychiatry Research</i> , 2015, 230, 628-636.	3.3	24
49	To flee, or not to flee, that is the question for older asylum seekers. <i>International Psychogeriatrics</i> , 2014, 26, 1403-1406.	1.0	18
50	Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. <i>BMC Neuroscience</i> , 2014, 15, 30.	1.9	18
51	Clozapine regulation of p90RSK and c-Fos signaling via the ErbB1-ERK pathway is distinct from olanzapine and haloperidol in mouse cortex and striatum. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 353-363.	4.8	23
52	Comorbid situs inversus totalis and schizophrenia in a young male. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 966-967.	2.3	1
53	Successful use of electroconvulsive therapy in a patient with atrial septal defect. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 493-494.	2.3	0
54	Are patients with schizophrenia impaired in processing non-emotional features of human faces?. <i>Frontiers in Psychology</i> , 2013, 4, 529.	2.1	40

#	ARTICLE	IF	CITATIONS
55	Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1149-1160.	2.1	27
56	Globalisation and mental health: The Lyon Declaration. <i>Asian Journal of Psychiatry</i> , 2012, 5, 283-285.	2.0	2
57	Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression. <i>Schizophrenia Research</i> , 2012, 138, 94-98.	2.0	20
58	The Third World Congress of Asian Psychiatry, Melbourne, Australia. <i>Asian Journal of Psychiatry</i> , 2011, 4, 230-231.	2.0	0
59	A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: A pilot randomised controlled trial. <i>Journal of Affective Disorders</i> , 2010, 120, 272-276.	4.1	68
60	Developing mental health resources for low and medium income countries of the Pacificâ€”The Cook Islands experience. <i>Asian Journal of Psychiatry</i> , 2010, 3, 47-48.	2.0	1
61	Evaluation of Treatment in 35 Cases of Bipolar Suicide. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 503-508.	2.3	45
62	Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. <i>Journal of Affective Disorders</i> , 2009, 116, 184-191.	4.1	83
63	Mirtazapine addâ€“on therapy in the treatment of schizophrenia with atypical antipsychotics: a doubleâ€“blind, randomised, placeboâ€“controlled clinical trial. <i>Human Psychopharmacology</i> , 2009, 24, 233-238.	1.5	60
64	Clozapine-Induced ERK1 and ERK2 Signaling in Prefrontal Cortex Is Mediated by the EGF Receptor. <i>Journal of Molecular Neuroscience</i> , 2009, 39, 185-198.	2.3	24
65	Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. <i>Molecular Psychiatry</i> , 2009, 14, 1017-1023.	7.9	132
66	Depression is greater in non-English speaking hospital outpatients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 83, e51-e53.	2.8	7
67	Regional update: Cambodia. <i>Asian Journal of Psychiatry</i> , 2009, 2, 120-121.	2.0	6
68	Assessing Nurse-Initiated Care in a Mental Health Crisis Assessment and Treatment Team in Australia. <i>Psychiatric Services</i> , 2009, 60, 1527-1531.	2.0	6
69	Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 474-478.	4.5	14
70	Psychosocial responses to disaster: An Asian perspective. <i>Asian Journal of Psychiatry</i> , 2008, 1, 7-14.	2.0	17
71	Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. <i>Psychiatry Research</i> , 2008, 158, 75-78.	3.3	33
72	Treatment with haloperidol and diazepam alters GABAA receptor density in the rat brain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 560-567.	4.8	14

#	ARTICLE	IF	CITATIONS
73	Cannabis and the brain. , 2007, , 81-100.		0
74	Altered Hippocampal Muscarinic M4, but Not M1, Receptor Expression from Subjects with Schizophrenia. Biological Psychiatry, 2007, 61, 1161-1170.	1.3	88
75	The Influence of Cannabis on the Developing Brain. Child and Adolescent Psychopharmacology News, 2007, 12, 6-9.	0.1	0
76	Challenges of post-tsunami reconstruction in Sri Lanka: health care aid and the Health Alliance. Medical Journal of Australia, 2006, 184, 23-26.	1.7	12
77	Dementia with Lewy Bodies (DLB) presenting with catatonic symptoms. Psychogeriatrics, 2006, 6, 31-34.	1.2	8
78	Cannabis and neurodevelopment: implications for psychiatric disorders. Human Psychopharmacology, 2006, 21, 245-254.	1.5	75
79	Clozapine decreases [3H] CP 55940 binding to the cannabinoid1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 371, 428-433.	3.0	41
80	Satisfying Competing Stakeholder Needs in a Depression Awareness Project. Evaluation Journal of Australasia, 2005, 5, 25-32.	0.6	2
81	The endogenous cannabinoid system in schizophrenia. , 2004, , 127-141.		2
82	Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disorders, 2003, 5, 257-264.	1.9	116
83	Substance misuse in patients with schizophrenia: a primary care guide. Medical Journal of Australia, 2003, 178, S71-5.	1.7	15
84	Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics. Current Molecular Medicine, 2003, 3, 393-407.	1.3	8
85	Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 2001, 103, 9-15.	2.3	374
86	Typical and atypical neuroleptic drugs decrease platelet 3H-dopamine uptake in the rat. Psychiatry Research, 1996, 62, 259-263.	3.3	1
87	The development of a method to measure [3H] dopamine uptake by washed platelets provides no evidence for circulating inhibitors of platelet dopamine uptake in schizophrenia. Biological Psychiatry, 1994, 36, 595-600.	1.3	7
88	NEUROLEPTICS AFFECT DOPAMINE UPTAKE BY PLATELETS FROM SCHIZOPHRENIC SUBJECTS. , 1994, , .		0
89	Postmortem studies of the brain cannabinoid system in schizophrenia. , 0, , 184-192.		0